Abstract
Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have